Arnold Bolomsky

Lenalidomide downregulates the cell survival factor, interferon regulatory factor‐4, providing a potential mechanistic link for predicting response

Antonia Lopez‐Girona, Daniel Heintel, Ling‐Hua Zhang et al. · British Journal of Haematology · 2011 · 177 citations · Full text

Potential Mechanistic Link, Mixed-phenotype Acute Leukemia, Immunology +24

High expression of cereblon (<i><scp>CRBN</scp></i>) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone

Daniel Heintel, Alberto Rocci, Heinz Ludwig et al. · British Journal of Haematology · 2013 · 121 citations · Full text

Immunodeficiencies, Immunology, Immune Regulation +25

Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment

Arnold Bolomsky, Karin Schlangen, Wolfgang Schreiner et al. · Journal of Hematology & Oncology · 2016 · 51 citations · Full text

The anti‐mitotic agents PTC‐028 and PTC596 display potent activity in pre‐clinical models of multiple myeloma but challenge the role of <i>BMI‐1</i> as an essential tumour gene

Arnold Bolomsky, Joséphine Muller, Kathrin Stangelberger et al. · British Journal of Haematology · 2020 · 32 citations · Full text

Immunomodulatory drugs thalidomide and lenalidomide affect osteoblast differentiation of human bone marrow stromal cells in vitro

Arnold Bolomsky, Martin Schreder, Tobias Meißner et al. · Experimental Hematology · 2014 · 30 citations

Bone Marrow Failure, Bone Morphogenic Protein, Medicine +9